OTLK Nov 2024 7.500 call
| Previous close | 1.8200 |
| Open | 1.8000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 7.50 |
| Expiry date | 2024-11-15 |
| Day's range | 1.8000 - 1.8200 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Simply Wall St.Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) largest shareholders are individual investors with 31% ownership, private equity firms own 31%
Key Insights The considerable ownership by individual investors in Outlook Therapeutics indicates that they...
GlobeNewswireOutlook Therapeutics® to Present at the Virtual Investor Pitch Conference
Live video webcast on Tuesday, June 18th at 12:00 PM ET ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, today announced that it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 12:00 PM ET. As part of the event, Russell Trenary, President and Chief Executi
- GlobeNewswire
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet AMDEuropean Commission decision applies automatically to all 27 EU Member States and, within 30 days, also to Iceland, Norway and LiechtensteinLYTENAVA™ (bevacizumab gamma) receives ten years of market exclusivity in EUAdvancing toward commercial launch of LYTENAVA™ (bevacizumab gamma) in EU expected in calendar Q1 2025Strategic partner
